|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, April 23, 2016 ) The Pancreatic Cancer Therapeutics Market Report shows that there are currently no early detection methods in use for PC. Currently the best option for patient survival is resection which can triple five year survival rate to 15% compared to the unresectable stages of PC. Regrettably ~83% of patients present with advanced unresectable disease and patient prognosis is extremely poor. The majority of patients ultimately develop resistant disease, for whom treatment options have historically been limited, with treatment involving fluorouracil as a monotherapy or used in a combination therapy being standard. The recent approval of Onivyde for gemcitabine refractory disease in 2015 has improved survival of resistant patients, but there is a clear clinical need to diversify the treatment options for this patient cohort. The current late-stage drugs in development for PC address this clinical need; however, results so far have been limited in their efficacy, with none demonstrating clinically transformative efficacy or safety. As a result, the growth in PC prevalence as a result of a global aging population, increasing diabetes and obesity prevalence is expected to be the key driver of this market throughout the forecast period.
Other Key Points in Report:
Global revenues for the PC market are forecast to rise at a moderate CAGR of 7.6% from $1.746bn in 2014 to $2.92bn in 2021.
-What factors are driving the market growth?
-How can the factors limiting growth be overcome in the future?
The variation in mechanism of action has shifted away from the traditional chemotherapies, which dominate the marketed products, but account for only 7% of the pipeline. 44% of the pipeline are drugs inhibiting signal transduction.
-What are the dynamics of the remaining 49% of the pipeline?
-How does this reflect the need for novel targeted therapies?
Key mechanisms of action across the pipeline include cancer immunotherapies against IAP repeat containing proteins, whole cell vaccines and targeted therapies against the PI3K/Akt/mTOR pathway.
-What is the scientific rationale behind these targets?
Several drugs are expected to be approved during the forecast period: TH-302, ruxolitinib phosphate, HyperAcute Pancreas, G17DT and clivatuzumab tetraxetan. However, their sales will be limited by their expected high costs.
Inquire before Buying Report@ http://www.reportsweb.com/inquiry&RW0001170037/buying
Table of Content: An Overview
2 Introduction 11
2.1 Disease Introduction 11
2.2 Epidemiology 11
2.3 Symptoms 12
2.4 Risk Factors 13
2.4.1 Age 13
2.4.2 Smoking 13
2.4.3 Obesity 13
2.4.4 Diet 13
2.4.5 Inherited Mutations 14
2.4.6 Chronic Pancreatitis 14
2.4.7 Diabetes 14
2.4.8 Infectious Diseases Risk Factors 14
2.4.9 Precursor Lesions 15
2.5 Pathophysiology 15
2.5.1 Somatic Mutations 15
2.6 Disease Stages 17
2.7 Diagnosis 18
2.8 Disease Prognosis 19
2.9 Treatment Algorithm 19
2.9.1 Adjuvant Therapy, Resected Cancer 20
2.9.2 First-Line Treatment, Unresectable 21
2.9.3 Second-Line Treatment, Unresectable 22
3 Commercial and Clinical Prospects of Marketed Products 24
3.1 Approved Products 24
3.1.1 Gemcitabine 24
3.1.2 IV Fluorouracil 25
3.1.3 Abraxane 26
3.1.4 Tarceva 27
3.1.5 Teysuno/TS-1/S-1 28
3.1.6 Onivyde 29
3.2 Off-Label Products 30
3.2.1 Capecitabine 30
3.2.2 Oxaliplatin 30
Ask for Discount on Report @ http://www.reportsweb.com/inquiry&RW0001170037/discount
4 Pipeline for Pancreatic Cancer Therapeutics 36
4.1 Overview by Phase and Molecule Type 37
4.2 Overview by Molecular Target 38
4.3 Clinical Trials 42
4.3.1 Clinical Trial Failure Rates 42
4.3.2 Clinical Trial Duration 46
4.3.3 Clinical Trial Size 50
4.3.4 Discussion 55
4.4 Promising Pipeline Molecules 55
4.4.1 Evofosfamide (TH-302)-Threshold Pharmaceuticals. 55
4.4.2 Tertomotide-Kael-GemVax 58
4.4.3 Ruxolitinib phosphate-Incyte Corporation 59
4.4.4 HyperAcute Pancreas/ Algenpantucel-L-NewLink Genetics Corporation 61
4.4.5 G17DT-Cancer Advances 64
4.4.6 Nimotuzumab-InnoMab 65
4.4.7 Clivatuzumab Tetraxetan-Immunomedics. 66
4.5 Pipeline Discussion 68
5 Market Forecast to 2021 72
5.1 Global Market 73
5.2 North America 74
5.2.1 US 74
5.2.2 Canada 77
Purchase Complete Report @ http://www.reportsweb.com/buy&RW0001170037/buy/4995
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
